Want to join the conversation?
$EXC 2Q15 Q&A: Jonathan of Deutsche Bank asked if it's fair to assume EXC has not done much in the way of 2018 hedging yet, and Joe said Exelon is behind its 2018 ratable sales plan. EXC has captured 2018 opportunities in retail and wholesale load-serving businesses to the extent possible, but to sell straight OTC power, it has not done much.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?